Journal of Thoracic Oncology (JTO), December 2022, Volume 17, Issue 12
Journal | English
Image For Activity Cover
Credit Offered
No Credit Offered
In This Issue
  • Research Watch/News in Brief
  • From the IASLC Tobacco Control Committee
  • Immune Checkpoint Inhibition for Locally Advanced NSCLC: Time to Ask New Questions?
  • Pericardial Mesothelioma, a Disease for Brave Hearts
Review Articles
  • Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
  • Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening
  • Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit
  • A Knock-In Mouse Model of Thymoma With the GTF2I L424H Mutation
  • YES1 Is a Druggable Oncogenic Target in SCLC
  • Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
  • Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial
Brief Report
  • Multimodality Therapy in Patients With Primary Pericardial Mesothelioma
Letters to the Editor
  • What About Palliative and Supportive Care Landscapes?
  • In Response: Letter Received From Dr. Tadashi Nishimura Titled “What About Palliative and Supportive Care Landscapes?”
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports
Powered By